Law360 (February 14, 2020, 10:20 PM EST) -- The Seventh Circuit on Friday rejected a startup's attempt to revive claims that a Pennsylvania pharmaceutical company reneged on a drug supply agreement and withheld its supply to manipulate profits, finding that the district court made no irreversible error.
In a unanimous, published decision, the panel affirmed a jury verdict that ended generic-drug supply claims brought by Illinois-based Antrim Pharmaceuticals LLC against rival Bio-Pharm Inc., saying the district court ruled correctly on various evidentiary and procedural questions.
Antrim had argued that the court should never have allowed Bio-Pharm's counterclaim for lost profits — counterclaims on which Antrim ultimately prevailed — to go...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!